AnaptysBio ( (ANAB) ) has released its Q3 earnings. Here is a breakdown of the information AnaptysBio presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in the development of innovative immunology therapeutics for autoimmune and inflammatory diseases, with a focus on pioneering treatments like rosnilimab and ANB033.
In its latest earnings report, AnaptysBio announced its financial results for the third quarter of 2025 and provided a business update. The company revealed plans to separate its biopharma operations from its royalty assets by the end of 2026, aiming to create two independent, publicly traded entities with distinct business objectives.
Key financial highlights include a significant increase in collaboration revenue, rising from $30 million in the third quarter of 2024 to $76.3 million in the same period of 2025, driven by strong sales of Jemperli, a PD-1 antagonist licensed to GSK. AnaptysBio also reported a net income of $15.1 million for the third quarter of 2025, a notable improvement from a net loss of $32.9 million in the previous year. The company anticipates a one-time $75 million milestone payment from GSK in the fourth quarter of 2025, contingent upon Jemperli achieving $1 billion in worldwide net sales.
Strategically, AnaptysBio is advancing its pipeline with promising candidates like rosnilimab, which showed positive Phase 2b data in rheumatoid arthritis and is undergoing a Phase 2 trial for ulcerative colitis. The company is also progressing with ANB033 in a Phase 1b trial for celiac disease and exploring additional indications.
Looking ahead, AnaptysBio’s management remains optimistic about the potential of its biopharma portfolio and the anticipated benefits of its strategic separation, positioning the company to capitalize on its innovative therapeutics and substantial royalty assets.